Patient Preference Between Cabazitaxel and Docetaxel for First-line Chemotherapy in Metastatic Castration-resistant Prostate Cancer: The CABADOC Trial

Giulia Baciarello; Remy Delva; Gwenaelle Gravis; Youssef Tazi; Philippe Beuzeboc; Marine Gross-Goupil; Emmanuelle Bompas; Florence Joly; Charlotte Greilsamer; Thierry Nguyen Tan Hon; Karim Fizazi; Groupe d’Etude des Tumeurs Uro-Genitales (Getug).

doi:https://doi.org/10.1016/j.eururo.2021.10.016

doi.org/10.1016/j.eururo.2021.10.016

Patient Preference Between Cabazitaxel and Docetaxel for First-line Chemotherapy in Metastatic Castration-resistant Prostate Cancer: The CABADOC Trial

,

,

..., Groupe d’Etude des Tumeurs Uro-Genitales (Getug).

1

European Urology23.40

Volume: 81, Issue: 3, Pages: 234 - 240

Published: Mar 1, 2022

Abstract

The taxanes docetaxel and cabazitaxel prolong overall survival for men with metastatic castration-resistant prostate cancer (mCRPC), with cabazitaxel approved in the postdocetaxel setting only. Recent data suggest they have similar efficacy but a different safety profile in the first-line mCRPC setting.To assess patient preference between docetaxel and cabazitaxel among men who received one or more doses of each taxane and did not experience...

Paper Fields

Paper Details

Title

Patient Preference Between Cabazitaxel and Docetaxel for First-line Chemotherapy in Metastatic Castration-resistant Prostate Cancer: The CABADOC Trial

DOI

doi.org/10.1016/j.eururo.2021.10.016

Published Date

Mar 1, 2022

Journal

European Urology

Volume

81

Issue

3

Pages

234 - 240

Citation AnalysisPro

You’ll need to upgrade your plan to Pro

Looking to understand the true influence of a researcher’s work across journals & affiliations?

Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.

Learn more

Notes

History